Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain (SUMMIT-07)

A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain

The purpose of this study is to determine whether a new opioid molecule, NKTR-181, is effective for the relief of moderate to severe chronic low back pain as compared to a placebo.

Study Overview

• Status: Completed
• Conditions: Low Back Pain; Chronic Pain
• Intervention / Treatment: Drug: NKTR-181 BID tablets; Drug: Placebo to match NKTR-181 BID tablets

Detailed Description

This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-control treatment of twelve weeks. During the double-blind treatment period, this study will evaluate the analgesic effect of NKTR-181 versus placebo in patients with moderate to severe chronic low back pain.

• Study Type: Interventional
• Enrollment (Actual): 1189
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Saraland, Alabama, United States, 36571
      • Investigator Site - Saraland
  • Arizona
    • Phoenix, Arizona, United States, 85023
      • Investigator Site - Phoenix
    • Tempe, Arizona, United States, 85283
      • Investigator Site - Tempe
  • Arkansas
    • Little Rock, Arkansas, United States, 72211
      • Investigator Site - Little Rock
  • Connecticut
    • Stamford, Connecticut, United States, 06905
      • Investigator Site - Stamford
  • Florida
    • Clearwater, Florida, United States, 33765
      • Investigator Site - Clearwater
    • Fort Lauderdale, Florida, United States, 33312
      • Investigator Site - Fort Lauderdale
    • Jacksonville, Florida, United States, 32257
      • Investigator Site - Jacksonville
    • Orlando, Florida, United States, 32806
      • Investigator Site - Orlando
    • Ormond Beach, Florida, United States, 32174
      • Investigator Site - Ormond Beach
    • Plantation, Florida, United States, 33324
      • Investigator Site - Plantation
    • Tampa, Florida, United States, 33603
      • Investigator Site - Tampa
    • West Palm Beach, Florida, United States, 33409
      • Investigator Site - West Palm Beach
  • Georgia
    • Atlanta, Georgia, United States, 30338
      • Investigator Site - Atlanta
    • Blue Ridge, Georgia, United States, 30513
      • Investigator Site - Blue Ridge
    • Marietta, Georgia, United States, 30060
      • Investigator Site - Marietta
    • Norcross, Georgia, United States, 30092
      • Investigator Site - Norcross
  • Illinois
    • Gurnee, Illinois, United States, 60031
      • Investigator Site - Gurnee
  • Iowa
    • West Des Moines, Iowa, United States, 50265
      • Investigator Site - West Des Moines
  • Kansas
    • Wichita, Kansas, United States, 67207
      • Investigator Site - Wichita
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • Investigator Site - Louisville
  • Louisiana
    • Bossier City, Louisiana, United States, 71111
      • Investigator Site - Bossier
    • New Orleans, Louisiana, United States, 70115
      • Investigator Site - New Orleans
    • Shreveport, Louisiana, United States, 71105
      • Investigator Site - Shreveport
  • Michigan
    • Bay City, Michigan, United States, 48706
      • Investigator Site - Bay City
    • Pinconning, Michigan, United States, 48706
      • Investigator Site - Pinconning
  • Mississippi
    • Biloxi, Mississippi, United States, 39531
      • Investigator Site - Biloxi
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Investigator Site - Saint Louis 1
    • Saint Louis, Missouri, United States, 63141
      • Investigator Site - Saint Louis 2
  • Nebraska
    • Omaha, Nebraska, United States, 68134
      • Investigator Site - Omaha
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Investigator Site - Las Vegas 2
    • Las Vegas, Nevada, United States, 89119
      • Investigator Site - Las Vegas 1
  • New York
    • Rochester, New York, United States, 14642
      • Investigator Site - Rochester
    • Williamsville, New York, United States, 14221
      • Investigator Site - Williamsville
  • North Carolina
    • Greensboro, North Carolina, United States, 27410
      • Investigator Site - Greensboro
    • Winston-Salem, North Carolina, United States, 27103
      • Investigator Site - Winston Salem
  • North Dakota
    • Fargo, North Dakota, United States, 58104
      • Investigator Site - Fargo
  • Ohio
    • Beavercreek, Ohio, United States, 45432
      • Investigator Site - Beavercreek
    • Cincinnati, Ohio, United States, 45219
      • Investigator Site - Cincinnati 1
    • Cincinnati, Ohio, United States, 45246
      • Investigator Site - Cincinnati 2
    • Columbus, Ohio, United States, 43235
      • Investigator Site - Columbus
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Investigator Site - Duncansville
    • Jenkintown, Pennsylvania, United States, 19046
      • Investigator Site - Jenkintown
  • South Dakota
    • Rapid City, South Dakota, United States, 57702
      • Investigator Site - Rapid City
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Investigator Site - Memphis
  • Texas
    • Arlington, Texas, United States, 76012
      • Investigator Site - Arlington
    • Austin, Texas, United States, 78731
      • Investigator Site - Austin
    • Killeen, Texas, United States, 76543
      • Investigator Site - Killeen
    • San Antonio, Texas, United States, 78229
      • Investigator Site - San Antonio
  • Utah
    • Salt Lake City, Utah, United States, 84124
      • Investigator Site - Salt Lake City
    • West Jordan, Utah, United States, 84088
      • Investigator Site - West Jordan
  • Virginia
    • Midlothian, Virginia, United States, 23114
      • Investigator Site - Midlothian
    • Norfolk, Virginia, United States, 23507
      • Investigator Site - Norfolk
  • Wisconsin
    • Kenosha, Wisconsin, United States, 53142
      • Investigator Site - Kenosha

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or non-pregnant, non-nursing female aged 18 to 75 years old
• Clinical diagnosis of moderate to severe, chronic non-neuropathic low back pain for at least six months
• Not experiencing adequate pain relief or have failed previous treatment with non-opioid analgesics
• Opioid analgesia is necessary
• Currently taking no more than 10 mg morphine sulfate equivalents per day of short acting opioids for 14 days prior to entry
• Females of child bearing potential must be using a highly effective form of birth control. All subjects must agree to use double-barrier contraception during participation in this study and for at least 2 months after the last dose of the study drug.
• Willing and able to provide informed consent

Exclusion Criteria:

• Taking extended release or long-acting opioids within 6 months
• History of hypersensitivity, intolerance, or allergy to opioids
• Compression of spinal nerve root; spinal fracture, tumor, or abscess
• Surgical procedures on the low back in the last 12 months or facet nerve root block or radiofrequency ablation in the last 3 months
• Untreated moderate to severe sleep apnea

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NKTR-181; NKTR-181 twice daily (BID) tablets	Drug: NKTR-181 BID tablets; NKTR-181 tablets 100-400 mg twice daily (BID)
Placebo Comparator: Placebo; Placebo to match NKTR-181 twice daily (BID) tablets	Drug: Placebo to match NKTR-181 BID tablets; Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Change in Weekly (ie, 7-day Average) Pain Score at the End of Double-blind, Randomized Treatment Period, Relative to the Weekly Score at the End of Titration (Double-blind Baseline)	The daily pain intensity is an 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).	12 Weeks of randomized double blinded period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Responder Analysis Based on Percent Reduction in Pain Intensity	A responder is defined by the Sponsor as a randomized subject who completes the double-blind Randomized Treatment Period and experiences improvement in the Week 12 Weekly Pain Score from Screening Pain Score. This includes the proportion of responders with at least 30% and at least 50% reduction in pain intensity.	Screening Baseline through Week 12
Patient Global Impression of Change (PGIC): Number of Responders	The PGIC assesses the change in overall status relative to the initiation of the treatment. The scale measures global change of overall status on a 7-point scale (1 = No change (or condition has got worse), 2 = Almost the same, 3 = A little better, 4 = Somewhat better, 5 = Moderately better, 6 = Better, 7 = A great deal better). The proportion of subjects responding " A great deal better " and "better" was summarized by treatment group.	Screening Baseline through Week 12
Change in Sleep Quality in the Medical Outcome Study Sleep Scale - Revised (MOS Sleep-R)	The MOS Sleep Scale measure sleep parameters contains 12 items. Eleven of them scored using a 5-point response scale and across 5 dimensions of sleep, including disturbance (4 items), sleep problems index (9 items), somnolence (3 items), adequacy (2 items), and respiratory impairments (2 items). The original survey items are converted to a 0 to 100 range (by Converting 1 to 0, 2 to 25, 3 to 50, 4 to 75, and 5 to 100). Items in each dimension (disturbance, sleep problems index, somnolence, adequacy, respiratory impairments) of sleep are averaged together to create the score for the scale. The range of each sleep dimension is from 0 to 100. Higher score of sleep disturbance, somnolence, sleep indices, and respiratory impairments indicates relatively worse sleep problem, whereas lower scores for sleep adequacy indicate worse sleep problems.	Screening Baseline through Week 12
Change in Sleep Quantity Measure in Hours in the Medical Outcome Study Sleep Scale - Revised (MOS Sleep-R)	The 12 items of the MOS Sleep Scale measure sleep parameters across 6 dimensions of sleep, including disturbance (4 items), sleep problems index (9 items), quantity (1 item), somnolence (3 items), adequacy (2 items), and respiratory impairments (2 items). One of the 12 items, Sleep quantity, records the actual number of hours slept. Reported here is the sleep quantity.	Screening Baseline through Week 12
Change in Roland Morris Disability Questionnaire (RMDQ)	The RMDQ contains 24 items that is used to quantify the impact of low back pain on subject's ability to perform daily activities, mood and sleep. The questionnaire consists of 24 statements derived from the Sickness Impact Profile, with the addition of the phrase "because of my back." The questionnaire covers the areas of mobility, self-care, and sleeping. The RMDQ score is the total number of items checked which is from a minimum of 0 to a maximum of 24; the greater the score the grater the physical disability due to lower back pain.	Screening Baseline through Week 12

Collaborators and Investigators

• Sponsor: Nektar Therapeutics

Publications and helpful links

General Publications

• Markman J, Gudin J, Rauck R, Argoff C, Rowbotham M, Agaiby E, Gimbel J, Katz N, Doberstein SK, Tagliaferri M, Lu L, Siddhanti S, Hale M. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. Pain. 2019 Jun;160(6):1374-1382. doi: 10.1097/j.pain.0000000000001517.

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2015
• Primary Completion (Actual): December 1, 2016
• Study Completion (Actual): February 1, 2017

Study Registration Dates

• First Submitted: February 9, 2015
• First Submitted That Met QC Criteria: February 12, 2015
• First Posted (Estimate): February 13, 2015

Study Record Updates

• Last Update Posted (Actual): September 16, 2020
• Last Update Submitted That Met QC Criteria: September 14, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Back Pain; Low Back Pain; Chronic Pain
• Other Study ID Numbers: 14-181-07